Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$630.6m

Verve Therapeutics Past Earnings Performance

Past criteria checks 0/6

Verve Therapeutics's earnings have been declining at an average annual rate of -35.5%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 127.8% per year.

Key information

-35.5%

Earnings growth rate

61.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate127.8%
Return on equity-33.8%
Net Margin-1,226.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Revenue & Expenses Breakdown

How Verve Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:VERV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2416-197520
31 Dec 2312-200500
30 Sep 238-193490
30 Jun 235-192470
31 Mar 233-179430
31 Dec 222-157380
30 Sep 221-148330
30 Jun 220-12529-25
31 Mar 220-13724-11
31 Dec 210-120190
30 Sep 210-1131416
30 Jun 210-991048
31 Mar 210-53740
31 Dec 200-4650

Quality Earnings: VERV is currently unprofitable.

Growing Profit Margin: VERV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VERV is unprofitable, and losses have increased over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare VERV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: VERV has a negative Return on Equity (-33.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.